乳腺癌相关分子标记物研究进展

Advances in molecular markers of breast cancer

  • 摘要: 分子标记物对于疾病诊断、评估预后和预测疗效有其独特的优势,也是乳腺癌领域研究的热点。目前除了已经明确与乳腺癌密切相关的分子标记物ER、PR和HER2外,还发现许多新的分子标记物,包括受体类分子如表皮生长因子受体、血管内皮生长因子、Ki67、雄激素受体等,PI3K/AKT/mTOR信号通路,以及其他一些新型分子如聚腺苷二磷酸核糖聚合酶1、长链非编码RNA等。随着精准医学时代的到来,乳腺癌相关分子标记物的研究对于乳腺癌的个体化治疗具有重要的指导意义。

     

    Abstract: Molecular markers have unique advantages on disease diagnosis, prediction of prognosis and assessment of therapeutic reactions, and it also becomes a hot topic in the area of breast cancer.Except for the well-known breast cancer biomarkers ER, PR and HER2, in recent years, many potential biomarkers for breast cancer have been found, including epidermal growth factor receptor(EGFR), vascular endothelial growth factor(VEGF), Ki67, androgen receptor(AR), PI3K/AKT/mTOR signaling pathway, poly ADP-ribose polymerase 1(PARP-1), as well as long chain noncoding RNA(lncRNAs).With the approaching of precision medicine, molecular markers of breast cancer shows important guiding significance for personalised therapy.

     

/

返回文章
返回